Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: Role of PI3K, PKC and PLC pathways

British Journal of Pharmacology

Volumn 137, Issue 7, 2002, Pages 1021-1030

  Gélinas, David S ^a   Bernatchez, Pascal N ^a   Rollin, Simon ^a   Bazan, Nicolas G ^b   Sirois, Martin G ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

eNOS; NO; PAF; PI3K; PKC; PLA 2; PLC; VEGF

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; CALCIMYCIN; CALCIUM CHELATING AGENT; CALMODULIN INHIBITOR; CYCLIC GMP; EGTAZIC ACID; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; GINKGOLIDE B; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPASE C; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SERINE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VASCULOTROPIN; WORTMANNIN; 1,2-BIS(2-AMINOPHENOXY)ETHANE-N,N,N',N'-TETRAACETIC ACID; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANDROSTANE DERIVATIVE; BISINDOLYLMALEIMIDE I; CALCIUM; CELL SURFACE RECEPTOR; CHELATING AGENT; CHROMONE DERIVATIVE; DITERPENE; DRUG DERIVATIVE; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GINKGOLIDE; INDOLE DERIVATIVE; IONOPHORE; ISOBUTYLMETHYLXANTHINE; LACTONE; LYMPHOKINE; MALEIMIDE DERIVATIVE; MORPHOLINE DERIVATIVE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; RO 31-8220; SIGNAL PEPTIDE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CATTLE; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TIME; VASCULAR ENDOTHELIUM;

1-METHYL-3-ISOBUTYLXANTHINE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; CALCIMYCIN; CALCIUM; CATTLE; CELLS, CULTURED; CHELATING AGENTS; CHROMONES; CYCLIC GMP; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; EGTAZIC ACID; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GINKGOLIDES; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; IONOPHORES; LACTONES; LYMPHOKINES; MALEIMIDES; MORPHOLINES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; PHOSPHOLIPASE C; PHOSPHORYLATION; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SERINE; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036899189     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704956     Document Type: Article

References (42)

1. Bernatchez, P.N., Allen, B.G., Gélinas, D.S., Guillemette, G. & Sirois, M.G (2001b). Regulation of VEGF-induced endothelial cell PAF synthesis: Role of p42/44 MAPK, p38 MAPK and PI3K pathways. Br. J. Pharmacol., 134, 1253-1262.
2. Bernatchez, P.N., Soker, S. & Sirois, M.G. (1999). Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is F1k-1-dependent. J. Biol. Chem., 274, 31047-31054.
3. 2. Br. J. Pharmacol., 134, 197-205.
4. Bligh, E.G. & Dyer, W.J. (1959). A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol., 37, 911-917.
5. 2+ and von Willebrand factor release in human endothelial cells. Am. J. Pathol., 138, 213-221.
6. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endotheliaI growth factor-exposed endothelial cells. J. Biol. Chem., 276, 32663-32669.
7. Busse, R. & Mulsch, A. (1990). Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated calmodulin. FEBS Lett., 265, 133-136.
8. Bussolati, B., Dunk, C., Grohman, M., Kontos, C.D., Mason, J. & Ahmed, A. (2001). Vascular endothelial growth factor receptor-1 modulates vascular growth factor-mediated angiogenesis via nitric oxide. Am. J. Physiol., 159, 993-1008.
9. Connolly, D.T., Heuvelman, D.M., Nelson, R., Olander, J.V., Eppley, B.L., Delfino, J.J., Siegel, N.R., Limgruber, R.M. & Feder, J. (1989). Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest., 84, 1470-1478.
10. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. & Zeiher, A.M. (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399, 601-605.
11. Feng, Y., Venema, V.J., Venema, R.C., Tsai, N. & Caldwell, R.B. (1999). VEGF induces nuclear translocation of F1k-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem. Biophys. Res. Commun., 256, 192-197.
12. Ferrara, N. (1995). Vascular endotheliaI growth factor. The trigger for neovascularization in the eye. Lab. Invest., 72, 615-618.
13. Ferrara, N. & Davis-Smith, T. (1997). The biology of vascular endothelial growth factor. Endo. Rev., 18, 4-25.
14. 2+/Calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res., 88, e68-e75.
15. Folkman, J. (1991). What is the evidence that tumors are angiogenesis-dependent? J. Natl. Cancer Inst., 82, 4-6.
16. Folkman, J. & Klagsbrun, M. (1987). Angiogenic factors. Science, 235, 442-447.
17. Fulton, D., Gratton, J-P., McCabe, T.J., Fontana, J., Fujio, Y., Walsh, K., Franke, T.F., Papapetropoulos, A. & Sessa, W.C. (1999). Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 399, 597-601.
18. Govers, R. & Rabelink, T.J. (2001). Cellular regulation of endothelial nitric oxide synthase. Am. J. Physiol., 280, F193-F206.
19. Gratton, J-P., Fontana, J., O'Connor, D.S., García-Cardeña, G., McCabe, T.J. & Sessa, W.C. (2000). Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and Caveolin-1 complex in vitro. J. Biol. Chem., 275, 22268-22272.
20. He, H., Venema, V.J., Gu, X., Venema, R.C., Marrero, M.B. & Caldwell, R.B. (1999). Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through F1k-1/KDR activation of c-Src. J. Biol. Chem., 274, 25130-25135.
21. Ishii, K., Chang, B., Kerwin Jr, J.F., Wagenaar, F.L., Huang, Z.J. & Murad, F. (1991). Formation of endothelium-derived relaxing factor in porcine kidney epithelial LLC-PK1 cells: An intra- and intercellular messenger for activation of soluble guanylate cyclase. J. Pharmacol. Exp. Ther., 256, 38-43.
22. Kroll, J. & Waltenberger, J. (1999). A novel function of VEGF receptor-2 (KDR): Rapid release of nitric oxide in response to VEGF-A stimulation of endothelial cells. Biochem. Biophys. Res. Commun., 265, 636-639.
23. Ku, DD., Zaleski, J.K., Liu, S. & Brock, T.A. (1993). Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol., 265, H586-H592.
24. Lakshminarayanan, S., Antonetti, D.A., Gardner, T.W. & Tarbell, J.M. (2000). Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: The role of NO. Invest. Ophthalmol. Vis. Sci., 41, 4256-4261.
25. Lal, B.K., Varma, S., Pappas, P.J., Hobson II, R.W. & Duran, W.N. (2001). VEGF increases permeability of the endothelial cell monolayer by activation of PKB/Akt, endothelial nitric oxide, and MAP kinase pathways. Microvasc. Res., 62, 252-262.
26. Marcheselli, V.L. & Bazan, N.G. (1994). Platelet-activating factor is a messager in the electroconvulsive shock-induced transcriptional activation of c-fos and zif-268 in hippocampus. J. Neurosci. Res., 37, 54-61.
27. Marcheselli, V.L., Rossowska, M.J., Domingo, M.T., Braquet, P. & Bazan, N.G. (1990). Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J. Biol. Chem., 265, 9140-9145.
28. McCabe, T.J., Fulton, D., Roman, L.J. & Sessa, W.C. (2000). Enhanced electron flux and reduced calmodulin dissociation may explain "calcium-independent" eNOS activation by phosphorylation. J. Biol. Chem., 275, 6123-6128.
29. Michell, B.J., Chen, Z-P., Tiganis, T., Stapleton, D., Katsis, F., Power, D.A., Sim, A.T. & Kemp, B.E. (2001). Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem., 276, 17625-17628.
30. Michell, B.J., Griffiths, J.E., Mitchelhill, K.I., Rodriguez-Crespo, I., Tiganis, T., Bozinovski, S., Ortiz de Montellano, P.R., Kemp, B.E. & Pearson, R.B. (1999). The Akt kinase signals directly to endothelial nitric oxide synthase. Cur. Biol., 9, 845-848.
31. Montrucchio, G., Lupia, E., Battaglia, E., Del Sorbo, L., Boccellino, M., Emanuelli, G. & Camussi, G. (2000). Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. Arterioscler. Thromb. Vasc. Biol., 20, 80-88.
32. Moulton, K.S., Heller, E., Konerding, M.A., Flynn, E., Palinski, W. & Folkman, J. (1999). Angiogenesis inhibitors endostatin or TNP-470 reduce intimai neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation, 99, 1726-1732.
33. Papapetropoulos, A., García-Cardeña, G., Madri, J.A. & Sessa, WC. (1997). Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest., 100, 3131-3139.
34. Sirois, M.G. & Edelman, E.R. (1997). VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am. J. Physiol., 272, H2746-H2756.
35. Thuringer, D., Maulon, L. & Frelin, C. (2001). Rapid transactivation of the VEGF receptor KDR/F1k-1 by the bradykinin B2 receptor contributes to eNOS activation in cardiac capillary endothelial cells. J. Biol. Chem., 277, 2028-2032.
36. Tokumitsu, H. & Soderling, T.R. (1996). Requirements for calcium and calmodulin in the calmodulin kinase activation cascade. J. Biol. Chem., 271, 5617-5622.
37. Unemori, E.N., Ferrara, N., Bauer, E.A. & Amento, E.P. (1992). Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell. Physiol., 153, 557-562.
38. Wu, H.M., Yuan, Y., Zawieja, D.C., Tinsley, J. & Granger, H.J. (1999). Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am. J. Physiol., 276, H535-H542.
39. Xia, P., Aiello, L.P., Ishii, H., Jiang, Z.Y., Park, D.J., Robinson, G.S., Takagi, H., Newsome, W.P., Jirousek, M.R. & King, G.L. (1996). Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest., 98, 2018-2026.
40. Yang, C., Watson, R.T., Elmendorf, J.S., Sacks, D.B. & Pessin, J.E. (2000). Calmodulin antagonists inhibit insulin-stimulated GLUT4 (Glucose Transporter 4) translocation by preventing the formation of phosphatidyinositol 3,4,5- trisphosphate in 3T3L1 adipocytes, Mol. Endocrinol., 14, 317-326.
41. Yano, S., Tokumitsu, H. & Soderling, T.R. (1998). Calcium promotes cell survival through CaM-K Kinase activation of the protein-kinase-B pathway. Nature, 396, 584-587.
42. Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H-T., Donnini, S., Granger, H.J. & Bicknell, R. (1997). Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest., 99, 2625-2634.